Valink Therapeutics Ltd

Valink Therapeutics Ltd from London UK: a small company with an active status, was founded four years ago and employs eight people. It holds £636,763 in assets, operates from a real address, and is managed by a single director, although no owners are officially listed. The company irregularly imports machinery, boilers, and mechanical appliances; parts, with its last import operation occurring one month ago in September 2023.

The company’s website reveals a focus on revolutionizing cancer treatment through bispecific antibody drug conjugates (bsADCs). Valink Therapeutics is developing next-generation ADCs, aiming to improve function and cell selectivity by enabling dual targeting. The site highlights rapid drug candidate design and testing, utilizing the LiliumX discovery platform to unlock therapies for solid tumours. It also features news and updates, including recent appointments, presentations at industry events, and a rebrand. The company has a US presence with offices in Boston, Massachusetts.

Financially, Valink Therapeutics Ltd presents a mixed picture. While current assets remain relatively stable at £640,000, a slight increase from £610,000, net assets have significantly declined by 130%, dropping from £860,000 to £840,000. Bank borrowings have increased substantially, rising by 1,100% to £230,000, and cash reserves have decreased by 64%, falling to £150,000. Trade debtors have also risen significantly, increasing by 170% to £480,000. The company’s small size—meeting two of three criteria for a small company—allows for agility, but the sharp decline in equity and the increase in debt are concerning. There is no auditor mentioned, which is common for companies of this size. The company’s financial statements are unaudited.

Registered in England/Wales under the registration number 13077801, with a registered address at W12 0BZ., England, London, Imperial Translation & Innovation Hub, 84 Wood Lane.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.